What is a stock summary page? Click here for an overview.
Business Description
Karyopharm Therapeutics Inc
NAICS : 325412
SIC : 5999
ISIN : US48576U1060
Description
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.56 | |||||
| Equity-to-Asset | -1.13 | |||||
| Debt-to-Equity | -1.05 | |||||
| Debt-to-EBITDA | -5.04 | |||||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | -12.69 | |||||
| Beneish M-Score | -2.85 | |||||
| WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -25.7 | |||||
| 3-Year EBITDA Growth Rate | 38.2 | |||||
| 3-Year EPS without NRI Growth Rate | 9.9 | |||||
| 3-Year FCF Growth Rate | 12.5 | |||||
| 3-Year Book Growth Rate | -11.9 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 28.5 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 16.24 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 22.9 | |||||
| 9-Day RSI | 17.7 | |||||
| 14-Day RSI | 17.99 | |||||
| 3-1 Month Momentum % | -29.87 | |||||
| 6-1 Month Momentum % | -33.12 | |||||
| 12-1 Month Momentum % | -57.4 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.7 | |||||
| Quick Ratio | 1.64 | |||||
| Cash Ratio | 1.18 | |||||
| Days Inventory | 227.24 | |||||
| Days Sales Outstanding | 79.71 | |||||
| Days Payable | 265.39 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -18.5 | |||||
| Shareholder Yield % | -38.17 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 95.86 | |||||
| Operating Margin % | -82.24 | |||||
| Net Margin % | -52.62 | |||||
| FCF Margin % | -88.1 | |||||
| ROA % | -37.73 | |||||
| ROIC % | -550 | |||||
| 3-Year ROIIC % | 521.55 | |||||
| ROC (Joel Greenblatt) % | -783.81 | |||||
| ROCE % | -29.21 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 0.24 | |||||
| EV-to-EBIT | -3.11 | |||||
| EV-to-EBITDA | -3.13 | |||||
| EV-to-Revenue | 0.83 | |||||
| EV-to-Forward-Revenue | 0.82 | |||||
| EV-to-FCF | -0.93 | |||||
| Price-to-GF-Value | 0.24 | |||||
| Price-to-Median-PS-Value | 0.01 | |||||
| Earnings Yield (Greenblatt) % | -32.16 | |||||
| FCF Yield % | -368.01 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Karyopharm Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 134.335 | ||
| EPS (TTM) (€) | -14.155 | ||
| Beta | 1.1 | ||
| 3-Year Sharpe Ratio | -1.17 | ||
| 3-Year Sortino Ratio | -1.3 | ||
| Volatility % | 61.98 | ||
| 14-Day RSI | 17.99 | ||
| 14-Day ATR (€) | 0.344478 | ||
| 20-Day SMA (€) | 5.4297 | ||
| 12-1 Month Momentum % | -57.4 | ||
| 52-Week Range (€) | 3.13 - 19.004999 | ||
| Shares Outstanding (Mil) | 8.42 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Karyopharm Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Karyopharm Therapeutics Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Karyopharm Therapeutics Inc Frequently Asked Questions
What is Karyopharm Therapeutics Inc(FRA:25K0)'s stock price today?
The current price of FRA:25K0 is €3.39. The 52 week high of FRA:25K0 is €19.00 and 52 week low is €3.13.
When is next earnings date of Karyopharm Therapeutics Inc(FRA:25K0)?
The next earnings date of Karyopharm Therapeutics Inc(FRA:25K0) is 2025-05-08 Est..
Does Karyopharm Therapeutics Inc(FRA:25K0) pay dividends? If so, how much?
Karyopharm Therapeutics Inc(FRA:25K0) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers